Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-018532
Filing Date
2021-05-06
Accepted
2021-05-06 21:18:21
Documents
2
Period of Report
2021-05-06

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2798
2 EX-24 DOCUMENT attachment1.htm EX-24 4547
  Complete submission text file 0000899243-21-018532.txt   8718
Mailing Address 430 EAST 29TH STREET SUITE 1040 NEW YORK NY 10016
Business Address
Shah Gaurav (Reporting) CIK: 0001725922 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40384 | Film No.: 21899929

Mailing Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202
Business Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202 502-569-1059
Talaris Therapeutics, Inc. (Issuer) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)